Foamulator, I appreciate the compliments and share your passion for BioCurex. Here are my thoughts on your questions:
1) The pinks are very important, and I'm 100% confident we'll get off them soon. You have to remember we're dealing with an extremely cash strapped company that is, for lack of a better word, pretty unprofessional. If Moro had a proper IB relationship and was better capatilized, we would have had the licensing deal years ago along with peer-reviewed publishing, larger trials, top brass management, amex/naz listing, etc, etc. But, unfortunately we aren't properly capitalized (a measly $50k at hand as of the recent 10-k). So we'll get everything done, but with delays. Sucks :(
2) I have no clue what you're referring about using RECAF for "immunization"? Would you mind posting the question on the ragingbull board as there are a few docs over there.
3) Re anti-cancer agents, it is still very much in the plan. If you notice on the 10-k they filed a few weeks ago, their pro forma R&D budget for FY05 really emphasizes the tumor imaging and therapeutic applications for RECAF. Also, the recent interview with Wittenberg discusses it, and if you call the company and talk to the lab personnel you'll see that they are very very excited about that aspect of the technology. Personally...I'm not very excited about the therapeutic application because it will take 5 years plus to monetize. The tumor imaging market, however, is also a huge market that is similar to diagnostics in the sense that the regulatory bar is very low (trials can take a few months rather than years). That appeals to me more than the traditional, three phase trial process that drugs have to deal with.
4) Re ROCHE...I agree with you totally and I think they will be our next partner. My guess is that Roche Diagnostics and Ortho-Clinical (JnJ's diagnostics unit) will be our next two partners. The company wasn't bulls**ting us before, when they said a deal is coming with a large pharma, so I doubt they are bulls**ting us now. The recently filed 10-k is very clear that they "expect" to license the technology to other "major" pharma company's in the "near-term." They couldn't be more clear, and I think Roche is a sure bet.
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.
